" What lies behind us, what lies before us, are small matters compared to what lies within us" R.W. Emmerson
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Human BioSystems to Receive its 4th U.S. Patent: 'Preservation of Blood Platelets with Citrate'
TUESDAY, MAY 16, 2006 11:49 AM
- Market Wire
HBSC
0.205 -0.025 News
Enter Symbol:
Enter Keyword:
PALO ALTO, CALIFORNIA, May 16, 2006 (MARKET WIRE via COMTEX) -- On the heels of its earlier announcement regarding the receipt of a third patent (U.S. Patent #7,029,839: "Methods & Solutions for Storing Donor Organs"), Human BioSystems (HBSC) announced today that it has been notified by the U.S. Patent Office that it will receive an additional patent titled "Preservation of Blood Platelets with Citrate". This patent grant further adds to the Company's increasing technology base covering a variety of cell preservation methods.
The two major recipient groups for blood platelets are cancer patients that have undergone chemotherapy and/or radiation treatment (about 70%), and trauma patients suffering from extensive bleeding.
"This new patent covers the process of cooling blood platelets to near zero degrees Centigrade to keep them fresh and preserved for greater than the current standard of 5 days. We anticipate being able to extend this process to 7 days and beyond. This will reduce the current need to discard stored platelets that have been preserved by existing methods," explained Dr. David Winter, President of Human BioSystems.
Current technology provides for the storage of platelets at room temperature. This allows any bacteria present to grow rapidly over the current 5-day allowable shelf period.
"By developing a cooling method that prolongs the preservation of platelets, we greatly reduce the risk of bacterial infection while increasing the availability of essential medical resources required to treat cancer and trauma patients," Dr. Winter stated.
Human BioSystems is a developer of preservation platforms for organs and other biomaterials. The Company, which is headquartered in Palo Alto, California with research facilities in Michigan, has made tremendous progress in its nine-year history. This fourth patent is another milestone for Human BioSystems. The Company is also currently conducting tests with two independent and FDA approved laboratories on its proprietary preservation methods.
Certain statements contained herein are "forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.
Contacts:
Human BioSystems
Harry Masuda
CEO
(650) 323-0943
hmasuda@humanbiosystems.com
Investor Relations
Yes International
Rich Kaiser
(800) 631-8127
rich@yesinternational.com
Investor Relations
Concept Communications, LLC
James D. Caldwell
(727) 447-0514
jca@concetcg.com
SOURCE: Human BioSystems
mailto:hmasuda@humanbiosystems.com
mailto:rich@yesinternational.com
mailto:jca@concetcg.com
Copyright 2006 Market Wire, All rights reserved.
Human BioSystems to Receive its 4th U.S. Patent: 'Preservation of Blood Platelets with Citrate'
TUESDAY, MAY 16, 2006 11:49 AM
- Market Wire
HBSC
0.205 -0.025 News
Enter Symbol:
Enter Keyword:
PALO ALTO, CALIFORNIA, May 16, 2006 (MARKET WIRE via COMTEX) -- On the heels of its earlier announcement regarding the receipt of a third patent (U.S. Patent #7,029,839: "Methods & Solutions for Storing Donor Organs"), Human BioSystems (HBSC) announced today that it has been notified by the U.S. Patent Office that it will receive an additional patent titled "Preservation of Blood Platelets with Citrate". This patent grant further adds to the Company's increasing technology base covering a variety of cell preservation methods.
The two major recipient groups for blood platelets are cancer patients that have undergone chemotherapy and/or radiation treatment (about 70%), and trauma patients suffering from extensive bleeding.
"This new patent covers the process of cooling blood platelets to near zero degrees Centigrade to keep them fresh and preserved for greater than the current standard of 5 days. We anticipate being able to extend this process to 7 days and beyond. This will reduce the current need to discard stored platelets that have been preserved by existing methods," explained Dr. David Winter, President of Human BioSystems.
Current technology provides for the storage of platelets at room temperature. This allows any bacteria present to grow rapidly over the current 5-day allowable shelf period.
"By developing a cooling method that prolongs the preservation of platelets, we greatly reduce the risk of bacterial infection while increasing the availability of essential medical resources required to treat cancer and trauma patients," Dr. Winter stated.
Human BioSystems is a developer of preservation platforms for organs and other biomaterials. The Company, which is headquartered in Palo Alto, California with research facilities in Michigan, has made tremendous progress in its nine-year history. This fourth patent is another milestone for Human BioSystems. The Company is also currently conducting tests with two independent and FDA approved laboratories on its proprietary preservation methods.
Certain statements contained herein are "forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.
Contacts:
Human BioSystems
Harry Masuda
CEO
(650) 323-0943
hmasuda@humanbiosystems.com
Investor Relations
Yes International
Rich Kaiser
(800) 631-8127
rich@yesinternational.com
Investor Relations
Concept Communications, LLC
James D. Caldwell
(727) 447-0514
jca@concetcg.com
SOURCE: Human BioSystems
mailto:hmasuda@humanbiosystems.com
mailto:rich@yesinternational.com
mailto:jca@concetcg.com
Copyright 2006 Market Wire, All rights reserved.
Human BioSystems to Receive its 4th U.S. Patent: 'Preservation of Blood Platelets with Citrate'
TUESDAY, MAY 16, 2006 11:49 AM
- Market Wire
HBSC
0.205 -0.025 News
Enter Symbol:
Enter Keyword:
PALO ALTO, CALIFORNIA, May 16, 2006 (MARKET WIRE via COMTEX) -- On the heels of its earlier announcement regarding the receipt of a third patent (U.S. Patent #7,029,839: "Methods & Solutions for Storing Donor Organs"), Human BioSystems (HBSC) announced today that it has been notified by the U.S. Patent Office that it will receive an additional patent titled "Preservation of Blood Platelets with Citrate". This patent grant further adds to the Company's increasing technology base covering a variety of cell preservation methods.
The two major recipient groups for blood platelets are cancer patients that have undergone chemotherapy and/or radiation treatment (about 70%), and trauma patients suffering from extensive bleeding.
"This new patent covers the process of cooling blood platelets to near zero degrees Centigrade to keep them fresh and preserved for greater than the current standard of 5 days. We anticipate being able to extend this process to 7 days and beyond. This will reduce the current need to discard stored platelets that have been preserved by existing methods," explained Dr. David Winter, President of Human BioSystems.
Current technology provides for the storage of platelets at room temperature. This allows any bacteria present to grow rapidly over the current 5-day allowable shelf period.
"By developing a cooling method that prolongs the preservation of platelets, we greatly reduce the risk of bacterial infection while increasing the availability of essential medical resources required to treat cancer and trauma patients," Dr. Winter stated.
Human BioSystems is a developer of preservation platforms for organs and other biomaterials. The Company, which is headquartered in Palo Alto, California with research facilities in Michigan, has made tremendous progress in its nine-year history. This fourth patent is another milestone for Human BioSystems. The Company is also currently conducting tests with two independent and FDA approved laboratories on its proprietary preservation methods.
Certain statements contained herein are "forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.
Contacts:
Human BioSystems
Harry Masuda
CEO
(650) 323-0943
hmasuda@humanbiosystems.com
Investor Relations
Yes International
Rich Kaiser
(800) 631-8127
rich@yesinternational.com
Investor Relations
Concept Communications, LLC
James D. Caldwell
(727) 447-0514
jca@concetcg.com
SOURCE: Human BioSystems
mailto:hmasuda@humanbiosystems.com
mailto:rich@yesinternational.com
mailto:jca@concetcg.com
Copyright 2006 Market Wire, All rights reserved.
HBSc... nice play athis level.. imho... .20x.21 10Q out yesterday... SLEPPING GIANT..imho
HBSC.... 4 MM on the bid at .20 2 MM on the ask at .21 then we see .25.... imho.. this is a buy
HBSc... .20x.21 4 MM on the bid at .20..... 2 MM on the ask at .21 then we are at .25 reasone to believe news is heades our way...only mho....
HBSc... 5 MM on bid at .20 on the ask.. 2 at .21 then we are at .25 BREAK OUT... imho
HBSc.. 10Q released yesterday.. .2001x.21 news is headeed our way on this ..imho... got a good feeling on this stock
HBSc... .2001x.21
4mm on the bid at ,20
HBSc.....2001x.21 4 MM on the bid at .20 10Q released yesterday... reason to believe NEWS is headed our way...imho
HBSC.. 10QSb released yesterday.... .205x.21 reason to believe =news is headed our way..imho
HBSC... .22.225 10-QSB released yesterday... reason to believe news is headed our way... imho
HBSC.. HUGE play tomorrow...imho
Everyone have a GREAT nite.... go HBSC tomorrow...
everyone have a great nite.... GO HBSC....
Take alook at the chart... we broke out of the .25 range and it setteled back... lots of support at the .20-.22 range
HBSC... .221x.23 110,500 vol.. something is up
HBSC waking up a bit.... .221x.23 what could be up???
HBSC.. wakeing up... quiet before the storm..... .221x.23
How are you doing Pie??.... hope u had a good weekend
HBSc.. nice play at .23
.226x.23 2 MM at the bid .22 4 MM at the bid .21 and 5 MM at the bid .20 reasone to believe news is headed our way....
HBSc...
total buy at this level.. .226x.23 2 MM on the bid at .22 4 on the bid at .21...6 MM on bid at .20 only up from here..lok at the chart..
HBSc.. .226x.23
2 MM at .22 on the bid 5 at .21 slepping giant dont be late to the party
HBSc very quiet.. quiet befoe the storm... great week last week... .23x.243... any takers...
HBSC.. about to make another move... 2 vol alerts issued last week...
broke out of the .25 range... reason to believe news is headed our way again... total buy at this level... setteled back .243...
HBSC... 24x.243...
reason to believe we will see the .30++++ range..
HBSC... making move today to the .30-.35++ range.. reason to believe more news is coming our way ..
gm.. shakerzzzzzzzzzzzzzzzzzzzzzzzz..
SGWV... reason to believe will start making a move today...
HBSC.. still going strong... .30+++ range reason to believe more news headed our way..
sorry.. must have made a mistake..... have a great week
ALERT on HBSC..
closed friday .24x.245 headed to .30 range IMHO..
HBSC... reason to believe News again VERY soon. This company has so much that is going on... more will be revealed as the days unfold... strong and long..